Jennifer Kim, PharmD

home / authors / jennifer-kim-pharmd

Articles

March 18th 2015

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease

David M. Kern, MS Stephanie DeVore, MSPH Jennifer Kim, PharmD Ozgur Tunceli, PhD Bingcao Wu, MS Boaz Hirshberg, MD

Targeting glucose control and managing cardiovascular (CV) risk factors may prevent future CV events, and have positive downstream impact by reducing costs to healthcare stakeholders.

September 15th 2008

Metastatic Non–Small Cell Lung Cancer: Costs Associated With Disease Progression

Kathleen M. Fox, MHS, PhD John M. Brooks, PhD Jennifer Kim, PharmD

The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.